KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Amortization - Intangibles (2017 - 2026)

TherapeuticsMD filings provide 6 years of Amortization - Intangibles readings, the most recent being $94000.0 for Q1 2026.

  • On a quarterly basis, Amortization - Intangibles rose 6.82% to $94000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $277000.0, a 77.53% decrease, with the full-year FY2025 number at $176000.0, down 86.12% from a year prior.
  • Amortization - Intangibles hit $94000.0 in Q1 2026 for TherapeuticsMD, up from $56000.0 in the prior quarter.
  • In the past five years, Amortization - Intangibles ranged from a high of $859000.0 in Q4 2024 to a low of $32000.0 in Q3 2025.
  • Median Amortization - Intangibles over the past 3 years was $95000.0 (2025), compared with a mean of $182555.6.
  • Biggest five-year swings in Amortization - Intangibles: tumbled 93.48% in 2025 and later grew 6.82% in 2026.
  • TherapeuticsMD's Amortization - Intangibles stood at $859000.0 in 2024, then tumbled by 93.48% to $56000.0 in 2025, then surged by 67.86% to $94000.0 in 2026.
  • The last three reported values for Amortization - Intangibles were $94000.0 (Q1 2026), $56000.0 (Q4 2025), and $32000.0 (Q3 2025) per Business Quant data.